EUCTR2006-002004-33-GB进行中（未招募）不适用
The effects of sitaxsentan once daily dosing on proteinuria, 24 hour systemic blood pressure and arterial stiffness in subjects with chronic kidney disease.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Has stage 1-5 chronic kidney disease (CKD) as defined by the kidney disease Outcomes Quality Initiative (K/DOQI) (using a 24 hour urine collection for creatinine clearance to estimate glomerular filtration rate(GFR)) with proteinuria, including any of the following aetiologies: immunoglobulin A (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy and membranous nephropathy.
- •2. Between 18 and 70 years of age, inclusive.
- •3. Has a body mass index (BMI) between 18 and 35 kg/m2, inclusive.
- •4. Is willing and able to adhere to the protocol requirements.
- •5. Provides written informed consent before any study procedure is performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Requires peritoneal dialysis or haemodialysis.
- •2. Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus membrane erythematosus, or known renovasular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.
- •3. Has a serum albumin in the nephritic range (<30 g/L) during Screening.
- •4. Has a sustained sitting systolic blood pressure (BP)> 160 mmHg or sustained sitting diastolic BP > 100 mmHg during screening.
- •5. Has a postural hypotension during screening which is defined as a decrease in systolic BP =20 mmHg and/or a decrease in diastolic BP =10 mmHg, comparing sitting and standing measurements.
- •6. Has a history and/or evidence of ischaemic heart disease.
- •7. Has or had a malignancy, with the exception of adequately-treated basal cell or squamous cell carcinoma of the skin that required significant medical intervention within the past 3 months and/or is likely to result in death within the next 2 years.
- •8. Has a history of allergies or hypersensitivity to sitaxentan or nifedipine or the excipients of either drug.
- •9. Has clinically significant psychiatric, addictive, neurological disease or any other condition that, in the Investigator’s opinion, would compromise his/her ability to give informed consent, participate fully in this study, prevent adherence to the requirements of the study protocol, or would compromise the interpretation of the data obtained from this study.
- •10. Uses a prohibited medication or plans to use a prohibited medication during the study. Prohibited medications include cyclosporine A, alternative endothelin (ET) receptor antagonist,phosphodiesterase inhibitors, and/or vitamin K antagonist (e.g warfarin). The intermittent use of phosphodiesterase inhibitors (e.g sildenafil) as needed” for erectile dysfunction is acceptable, however, as long as the subject is not dosed within 24 hours of an efficacy assessment.
- •11. Received treatment with an investigational drug or device within 30 days prior to study entry.
- •12. Has a history of organ transplantation.
- •13. Has atrial fibrillation requiring anticoagulation or a history (in the preceding 6 months) of any intermittent cardiac dysrhythmia that may require anticoagulation therapy.
- •14. Has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) level >1.5 x the upper limit of the normal range (ULN) at screening and/or serum total bilirubin > ULN
- •15. Has a haemoglobin concentration <8.0 mg/dL at screening.
- •16. Has a positive serological results for hepatitis B and/or hepatitis C.
- •17. Is a woman of childbearing potential who is willing to use 2 forms of contraceptive therapy, including at least 1 barrier method, throughout the study. (Women who are surgically sterile or who are post-menopausal for at least 2 years are not considered to be of childbearing potential.)
- •18. Is pregnant, lactating, or breastfeeding
- •19. Has, in the opinion of the investigator, a dependence on alcohol
- •20. Has, in the opinion of the investigator, a dependence on illicit drugs.
研究者
相似试验
已完成
2 期
Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease SubjectsChronic Kidney DiseaseNCT00810732Pfizer27
撤回
1 期
Effect Of Rifampin On Pharmacokinetics Of SitaxsentanPulmonary Arterial HypertensionNCT01251835Pfizer
终止
1 期
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesPulmonary Arterial HypertensionNCT01244620Pfizer16
进行中（未招募）
1 期
Evaluation of the impact of a Sandostatin injection before axillary node dissection on lymphorrhea in patients operated for breast cancerThe population includes all patients who must have an axillary node dissection for non-metastatic breast cancer.EUCTR2015-004337-27-FRInstitut de Cancérologie de l'Ouest67
已完成
不适用
Effect of administration of single dose Histidine-Tryptophane-Ketoglutarate (HTK) cardioplegia solution on serum sodium concentration, osmolarity and acid-base balance.electrolytstoornissen en stoornissen in osmolariteit en het zuur-base evenwichthyponatriemialow sodium concentrationNL-OMON43165Catharina-ziekenhuis50